Nasdaq

Mapi Pharma to Present Posters on GA Depot for Treating Relapsing Forms of Multiple Sclerosis (MS) and Primary Progressive Forms of Multiple Sclerosis at the American Academy ...

NESS ZIONA, Israel, March 31, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...
Yahoo Finance

Mapi Pharma Announces Positive Top-Line Results from GA Depot Phase III Trial for Relapsing forms of Multiple Sclerosis (RMS)

NESS ZIONA, Israel, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical company focused on introducing innovative long-acting depot ...
KTLA

Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis

PITTSBURGH and NESS ZIONA, Israel, Aug. 7, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Mapi Pharma Ltd., a fully integrated, late-stage clinical development ...
Mena FN

Mapi Pharma Receives Government of Israel Funding for the Establishment of a Finished Dosage Form Facility for the Manufacturing of GA Depot Pharmaceuticals

(MENAFN- GlobeNewsWire - Nasdaq) itemprop="articleBody">NESS ZIONA, Israel, March 18, 2019 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, clinical, late stage biopharmaceutical company, ...
Nasdaq

Mapi Pharma Announces Positive Top-Line Results from GA Depot Phase III Trial for Relapsing forms of Multiple Sclerosis (RMS)

The study evaluating a long-acting glatiramer acetate injection, GA Depot 40 mg once every four weeks, met the primary endpoint, significantly reducing the annualized relapse rate (ARR) by 30.1 ...